Company intelligence / Profile preview
AOP Health
Vienna, Austriaaop-health.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
AOP Health has successfully developed cancer stem cell targeting therapies and is expanding research with a first-in-class investigational oncology drug candidate (AOP208). The company has initiated the SERONCO-1 phase I clinical trial for solid tumors and lymphomas, with plans for a trial in acute myeloid leukemia expected to commence in 2026[2][3].
- Therapeutic areas
- OtherOncologyRare DiseasesHematology
- Modalities
- Small moleculesbiologics (including Ropeginterferon alfa-2b)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
PharmaEssentiaLeukos BiotechJosep-Carreras Leukemia Research InstituteVall d'Hebron Institute of Oncology (VHIO)
Beyond the preview
Go deeper on AOP Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AOP Health.